Xu Jiandong's Form 4 filing
Estrella Immunopharma, Inc. (ESLA) · filed Apr 29, 2026
- Accession no.
- 0001213900-26-049602
- Filed
- Apr 29, 2026
- Trade date
- Sep 11-Oct 7, 2025
- Filing delay
- 230 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.59K. It was filed 230 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Xu JiandongCIK 0001920399 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2025 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +100 | $1.04 | +$104 | 264,588 | Direct | |
| Sep 22, 2025 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +1,000 | $1.16 | +$1,160 | 16,700 | Indirect | |
| Oct 7, 2025 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +1,000 | $1.33 | +$1,330 | 265,488 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.